Main Article Content
Abstract
Background: Conventional chemotherapy is fundamentally constrained by its inability to distinguish between malignant and healthy cells, resulting in dose-limiting systemic toxicity that prevents administration of the drug concentrations required for complete tumor eradication. Stimuli-responsive drug delivery systems represent a sophisticated pharmacological engineering approach in which the drug release trigger is embedded within the pathophysiological environment of the disease site itself — exploiting the aberrant pH, elevated temperature, altered redox status, and dysregulated enzymatic activity that characterize the tumor microenvironment — to achieve spatially and temporally controlled drug release at the intended therapeutic site with minimal off-target exposure.
Objective: This review critically examines the scientific basis, design principles, nanocarrier platforms, characterization methods, mechanisms of stimuli-triggered drug release, and therapeutic applications of stimuli-responsive drug delivery systems, with particular focus on cancer therapy applications and recent research advances up to 2022.
Results and Discussion: Four principal endogenous stimuli — pH, temperature, redox potential, and enzyme activity — have been extensively exploited in nanocarrier design, individually and in dual or multi-stimuli combinations. pH-responsive systems exploit the acidic tumor microenvironment (pH 6.5 to 6.8 extracellular, pH 4.5 to 5.5 endosomal) to trigger drug release selectively in cancer tissues. Redox-responsive systems leverage the 100- to 1000-fold higher intracellular glutathione concentration in cancer cells compared to plasma to achieve cytoplasm-specific drug release. Enzyme-responsive systems utilize matrix metalloproteinases, cathepsins, and other tumor-overexpressed proteases as activation triggers. Dual and multi-stimuli responsive systems provide enhanced selectivity by requiring the simultaneous presence of two or more disease-specific conditions to initiate drug release.
Conclusion: Stimuli-responsive drug delivery systems offer a conceptually compelling approach to improving the therapeutic index of anticancer drugs by aligning the drug release event with the pathophysiological characteristics of the tumor microenvironment. Translation from preclinical promise to clinical products requires resolution of manufacturing scalability challenges, in vivo trigger fidelity validation, and demonstrated superiority over conventional formulations in randomized clinical trials.